Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline

Sakiko Minami, Norihiro Nagai, Misa Suzuki, Toshihide Kurihara, Hideki Sonobe, Mamoru Kamoshita, Atsuro Uchida, Hajime Shinoda, Hitoshi Takagi, Shozo Sonoda, Taiji Sakamoto, Kazuo Tsubota, Yoko Ozawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients exhibiting good BCVA at baseline. Twenty-nine treatment-naive AMD patients (29 eyes) with BCVA better than 0.6 (74 letters in ETDRS chart) were treated with IVA once a month for 3 months and every 2 months thereafter with no additional treatments. Improvement in mean BCVA, measured using the conventional Landolt C chart, contrast VA chart, and functional VA (FVA) system, and reductions in mean central retinal thickness (CRT), central choroidal thickness, macular volume (MV), and choroidal area on optical coherence tomography images were observed at 6 and 12 months. Improvements in contrast VA and FVA scores, in contrast to conventional BCVA, correlated with MV reduction; no VA scores correlated with a reduced CRT. The MV correlated with choroidal area after IVA. No severe adverse events occurred. IVA improved visual function, retinal condition, and quality of life evaluated by Visual Function Questionnaire, and was beneficial in these patients. The contrast VA and FVA scores and MVs, which detect subtle changes, helped demonstrate the benefits.

Original languageEnglish
Article number58
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Macular Degeneration
Visual Acuity
Therapeutics
Optical Coherence Tomography
aflibercept
Quality of Life
Clinical Trials

ASJC Scopus subject areas

  • General

Cite this

Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline. / Minami, Sakiko; Nagai, Norihiro; Suzuki, Misa; Kurihara, Toshihide; Sonobe, Hideki; Kamoshita, Mamoru; Uchida, Atsuro; Shinoda, Hajime; Takagi, Hitoshi; Sonoda, Shozo; Sakamoto, Taiji; Tsubota, Kazuo; Ozawa, Yoko.

In: Scientific Reports, Vol. 8, No. 1, 58, 01.12.2018.

Research output: Contribution to journalArticle

Minami, Sakiko ; Nagai, Norihiro ; Suzuki, Misa ; Kurihara, Toshihide ; Sonobe, Hideki ; Kamoshita, Mamoru ; Uchida, Atsuro ; Shinoda, Hajime ; Takagi, Hitoshi ; Sonoda, Shozo ; Sakamoto, Taiji ; Tsubota, Kazuo ; Ozawa, Yoko. / Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{a2898a5e4ecf4049a7aeecd60ca5eb4d,
title = "Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline",
abstract = "Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients exhibiting good BCVA at baseline. Twenty-nine treatment-naive AMD patients (29 eyes) with BCVA better than 0.6 (74 letters in ETDRS chart) were treated with IVA once a month for 3 months and every 2 months thereafter with no additional treatments. Improvement in mean BCVA, measured using the conventional Landolt C chart, contrast VA chart, and functional VA (FVA) system, and reductions in mean central retinal thickness (CRT), central choroidal thickness, macular volume (MV), and choroidal area on optical coherence tomography images were observed at 6 and 12 months. Improvements in contrast VA and FVA scores, in contrast to conventional BCVA, correlated with MV reduction; no VA scores correlated with a reduced CRT. The MV correlated with choroidal area after IVA. No severe adverse events occurred. IVA improved visual function, retinal condition, and quality of life evaluated by Visual Function Questionnaire, and was beneficial in these patients. The contrast VA and FVA scores and MVs, which detect subtle changes, helped demonstrate the benefits.",
author = "Sakiko Minami and Norihiro Nagai and Misa Suzuki and Toshihide Kurihara and Hideki Sonobe and Mamoru Kamoshita and Atsuro Uchida and Hajime Shinoda and Hitoshi Takagi and Shozo Sonoda and Taiji Sakamoto and Kazuo Tsubota and Yoko Ozawa",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-017-18255-4",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline

AU - Minami, Sakiko

AU - Nagai, Norihiro

AU - Suzuki, Misa

AU - Kurihara, Toshihide

AU - Sonobe, Hideki

AU - Kamoshita, Mamoru

AU - Uchida, Atsuro

AU - Shinoda, Hajime

AU - Takagi, Hitoshi

AU - Sonoda, Shozo

AU - Sakamoto, Taiji

AU - Tsubota, Kazuo

AU - Ozawa, Yoko

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients exhibiting good BCVA at baseline. Twenty-nine treatment-naive AMD patients (29 eyes) with BCVA better than 0.6 (74 letters in ETDRS chart) were treated with IVA once a month for 3 months and every 2 months thereafter with no additional treatments. Improvement in mean BCVA, measured using the conventional Landolt C chart, contrast VA chart, and functional VA (FVA) system, and reductions in mean central retinal thickness (CRT), central choroidal thickness, macular volume (MV), and choroidal area on optical coherence tomography images were observed at 6 and 12 months. Improvements in contrast VA and FVA scores, in contrast to conventional BCVA, correlated with MV reduction; no VA scores correlated with a reduced CRT. The MV correlated with choroidal area after IVA. No severe adverse events occurred. IVA improved visual function, retinal condition, and quality of life evaluated by Visual Function Questionnaire, and was beneficial in these patients. The contrast VA and FVA scores and MVs, which detect subtle changes, helped demonstrate the benefits.

AB - Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients exhibiting good BCVA at baseline. Twenty-nine treatment-naive AMD patients (29 eyes) with BCVA better than 0.6 (74 letters in ETDRS chart) were treated with IVA once a month for 3 months and every 2 months thereafter with no additional treatments. Improvement in mean BCVA, measured using the conventional Landolt C chart, contrast VA chart, and functional VA (FVA) system, and reductions in mean central retinal thickness (CRT), central choroidal thickness, macular volume (MV), and choroidal area on optical coherence tomography images were observed at 6 and 12 months. Improvements in contrast VA and FVA scores, in contrast to conventional BCVA, correlated with MV reduction; no VA scores correlated with a reduced CRT. The MV correlated with choroidal area after IVA. No severe adverse events occurred. IVA improved visual function, retinal condition, and quality of life evaluated by Visual Function Questionnaire, and was beneficial in these patients. The contrast VA and FVA scores and MVs, which detect subtle changes, helped demonstrate the benefits.

UR - http://www.scopus.com/inward/record.url?scp=85042787046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042787046&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-18255-4

DO - 10.1038/s41598-017-18255-4

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 58

ER -